Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nash Pharmaceuticals
Canada
- Ownership
- Private
- Development stage
- Other
01
Overview
Nash Pharmaceuticals has identified multiple drug candidates through repurposing approved drugs. In NASH models, compounds achieved >2.5 point reduction in NAFLD score. In CKD models, three candidates reduced fibrosis scores to levels equivalent to Telmisartan with one showing superior kidney function improvement. In IBD models, two compounds demonstrated effectiveness comparable to 5-ASA in reducing disease severity.
- Therapeutic areas
- NephrologyGastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Nash Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nash Pharmaceuticals.